zh-twzhen
zh-twzhen

News

2021

Date

Title

2021-12-30

Oneness announces the information about the investor’s conference of 2021 Q4.

>
2021-12-30

Annouce the change of the spokesperson.

>
2021-12-22

Oneness announces the information about the investor’s conference of 2021 Q4.

>
2021-12-17

The Singapore Health Science Authority has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon

>
2021-12-16

Oneness Biotech Co., LTD. receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (Research code: ON101)

>
2021-12-13

The partial efficacy data for the Phase 2a study of FB825 in the treatment of atopic dermatitis in the U.S. have been analyzed

>
2021-12-03

The mechanism of action and Phase 3 MRCT results of the diabetic foot ulcer new drug, Fespixon have been accepted for an oral presentation at IDF Congress 2021

>
2021-12-02

Oneness Biotech Co., Ltd. receives a Taiwan patent O titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” O on Fespixon cream (Research code: ON101).

>
2021-11-26

News-Press Release of The Publication the Ph3 Data And The Mechanism of Action of Fespixon（ON101）on JAMA Network Open

>
2021-11-15

Oneness Biotech and Tanner Pharma Group initiate early access program for Fespixon®, a novel macrophage-regulating new therapy for the treatment of diabetic foot ulcers

>
2021-11-12

News-Diabetes Self-Management:New Cream Cures Foot Ulcers

>
2021-10-22

Oneness Biotech Co., LTD. receives a Mexican patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2021-10-19

An Australian patent on the producing of recombinant glycoproteins with modified glycosylation was granted.

>
2021-10-13

A Malaysian patent on the Anti-CεMx (FB825) antibody was granted.

>
2021-10-12

Oneness has been notified by the US FDA on the acceptance of ON101 medical device 510(k) application

>